Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by askretkaon Apr 06, 2024 8:21am
178 Views
Post# 35974571

04 April 6.82% 0wned By Hedges and Institutions now

04 April 6.82% 0wned By Hedges and Institutions now

Link: 
https://www.marketbeat.com/instant-alerts/nasdaq-oncy-initiated-coverage-2024-04-04/

Scroll down a bit to get hedge fund stuff










Institutional Investors Weigh In On Oncolytics Biotech

A number of institutional investors have recently modified their holdings of the stock. International Assets Investment Management LLC raised its stake in shares of Oncolytics Biotech by 33.9% in the 4th quarter. International Assets Investment Management LLC now owns 269,699 shares of the company's stock valued at $364,000 after purchasing an additional 68,246 shares in the last quarter. Renaissance Technologies LLC raised its stake in shares of Oncolytics Biotech by 15.3% in the 1st quarter. Renaissance Technologies LLC now owns 129,856 shares of the company's stock valued at $156,000 after purchasing an additional 17,256 shares in the last quarter. Citadel Advisors LLC acquired a new stake in shares of Oncolytics Biotech in the 4th quarter valued at about $154,000. Advisor Resource Council acquired a new stake in shares of Oncolytics Biotech in the 4th quarter valued at about $135,000. Finally, BNP Paribas Arbitrage SNC raised its stake in shares of Oncolytics Biotech by 778.6% in the 2nd quarter. BNP Paribas Arbitrage SNC now owns 68,320 shares of the company's stock valued at $178,000 after purchasing an additional 60,544 shares in the last quarter. Institutional investors and hedge funds own 6.82% of the company's stock.

Cheers!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!

 

 

<< Previous
Bullboard Posts
Next >>